|
Metabolic indicators
|
Baseline
|
End of trial
|
|---|
|
Soy-nut
|
TSP
|
Control
|
P value
|
Soy-nut
|
TSP
|
Control
|
P value
|
|---|
|
TC (mg/dl)
|
229.9 ± 5.13
|
229.4 ± 5.84
|
233.2 ± 5.20
|
0.87
|
200.7 ± 4.82a
|
205.2 ± 5.55a
|
224.5 ± 5.21
|
< 0.001
|
|
TG (mg/dl)
|
212.1 ± 8.23
|
211.9 ± 8.86
|
212.6 ± 10.65
|
0.99
|
199.8 ± 8.65
|
200.3 ± 9.09
|
208.5 ± 10.79
|
0.77
|
|
HDL-C (mg/dl)
|
44.2 ± 1.38
|
43.0 ± 0.98
|
44.2 ± 1.58
|
0.78
|
46.3 ± 1.17
|
44.8 ± 0.93
|
43.7 ± 1.71
|
0.35
|
|
LDL-C (mg/dl)
|
154.0 ± 3.28
|
154.7 ± 5.80
|
152.3 ± 6.01
|
0.95
|
131.0 ± 5.42a
|
134.5 ± 5.65
|
151.5 ± 6.51
|
< 0.05
|
|
VLDL-C (mg/dl)
|
41.7 ± 1.56
|
42.4 ± 1.77
|
42.4 ± 2.19
|
0.95
|
34.5 ± 1.83a
|
37.4 ± 2.03
|
42.0 ± 2.28
|
< 0.05
|
|
Apo AI (g/l)
|
1.8 ± 0.20
|
1.7 ± 0.22
|
1.6 ± 0.22
|
0.77
|
2.0 ± 0.19
|
1.9 ± 0.22
|
1.6 ± 0.21
|
0.31
|
|
Apo B100(g/l)
|
1.5 ± 0.09
|
1.5 ± 0.10
|
1.5 ± 0.17
|
0.96
|
1.2 ± 0.07a
|
1.2 ± 0.09
|
1.6 ± 0.16
|
< 0.05
|
|
FBG (mg/dl)
|
104.8 ± 2.01
|
104.3 ± 2.32
|
102.5 ± 2.49
|
0.75
|
90.4 ± 2.18a
|
97.8 ± 2.34
|
99.6 ± 2.83
|
< 0.05
|
|
Insulin (µIU/ml)
|
12.8 ± 0.79
|
11.6 ± 0.95
|
13.4 ± 0.9
|
0.36
|
10.8 ± 0.79a
|
10.8 ± 0.85a
|
13.8 ± 0.90
|
< 0.05
|
|
HOMA-IR
|
3.4 ± 0.25
|
3.0 ± 0.27
|
3.4 ± 0.25
|
0.51
|
2.5 ± 0.21a
|
2.6 ± 0.23
|
3.4 ± 0.24
|
< 0.01
|
|
TG/HDL
|
4.9 ± 0.27
|
5 ± 0.25
|
4.9 ± 0.34
|
0.99
|
4.41 ± 0.24
|
4.5 ± 0.24
|
5 ± 0.39
|
0.35
|
|
CRP (µg/ml)
|
3.2 ± 0.37
|
3.1 ± 0.45
|
3.0 ± 0.49
|
0.97
|
2.9 ± 0.38
|
3.0 ± 0.39
|
3.0 ± 0.33
|
0.98
|
|
Fibrinogen (mg/dl)
|
316.7 ± 6.89
|
316.5 ± 8.88
|
314.2 ± 9.37
|
0.97
|
297.8 ± 6.07
|
302.0 ± 6.37
|
306.4 ± 6.59
|
0.63
|
|
MDA (µmol/l)
|
4.9 ± 0.36
|
4.9 ± 0.17
|
5.3 ± 0.28
|
0.48
|
4.2 ± 0.35a
|
4.3 ± 0.19a
|
5.3 ± 0.25
|
< 0.001
|
|
TAC (µmol/l)
|
1302.0 ± 45.36
|
1305.3 ± 45.37
|
1305.1 ± 40.09
|
0.99
|
1516.3 ± 39.70a
|
1503.4 ± 35.28a
|
1350.2 ± 47.38
|
< 0.01
|
- TSP: Textured soy protein; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: triglyceride; HDL-C: high density lipoprotein; LDL-C: low density lipoprotein; VLDL-C: very low density lipoprotein; Apo AI: apolipoprotein AI; Apo B100: apolipoprotein B100; FBG: fasting blood glucose; HOMA-IR: homeostasis model of assessment insulin resistance; TG/HDL-C: triglyceride/high density lipoprotein; MDA: malondialdehyde; TAC: total antioxidant capacity; CRP: C-reactive protein
- Values are mean ± standard error
- aThere was a significant difference in the treatment groups compared with control group (post hoc ANOVA)
